TOKYO: Japan’s health ministry has approved dexamethasone, a cheap and widely used steroid, as a second treatment of COVID-19 after a trial in Britain showed the drug reduced death rates in hospitalised patients.
The ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc’s antiviral drug remdesivir in a recent revision to its handbook. The revision was widely reported by Japanese media on Wednesday and was viewed by Reuters.
In results announced last month, a trial by researchers in the United Kingdom showed dexamethasone as the first drug to save lives of COVID-19 patients in what scientists said was a major breakthrough in the coronavirus pandemic.
The full results of the large randomised clinical trial released last Friday in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.
Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, and along with antibiotics in tuberculosis.
Related
Details of dexamethasone study showing reduced death risk released
Leave a Comment